Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK inhibitors for moderate to severe atopic dermatitis
ChiCTR2300071142Phase 4Suspended
- Sponsor
- Jining First People's Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of abrocitinib, tofacitinib and upadacitinib in atopic dermatitis (AD) (3 arms), sponsored by Jining First People's Hospital. Primary endpoints: Investigator's Global Assessment (IGA) score, Itching Visual Analogue Scale (VAS) score and 6 more. Started May 2023; status: suspended.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2300071142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071142.